Here’s Why Alnylam Pharmaceuticals (ALNY) Declined

Here’s Why Alnylam Pharmaceuticals (ALNY) Declined

Thu, September 10, 2026 at 2:44 PM GMT+3 3 min read

• ALNY +0.47%

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the "American Century Investments Focused Dynamic Growth Fund". The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback in June as momentum waned and investors anticipated potential interest rate hikes by the Federal Reserve. Growth and AI stocks outperformed value stocks, while large-cap companies generally surpassed small- and mid-cap stocks. Underperformance was noted in healthcare and communication services, while industrials, particularly in aerospace and defense, contributed positively to performance. The fund's investor class returned 16.38%, slightly below the Russell 1000 Growth Index's 16.74%. The investment approach focuses on bottom-up financial analysis to identify large-cap companies with long-term earnings growth potential, while aiming to mitigate non-financial risks. Please review the Fund's top five holdings to gain insights into its key selections for 2026.

In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company that discovers and commercializes therapeutics based on ribonucleic acid interference, detracted from the Fund's performance this quarter. On September 09, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed at $258.00 per share. Over the past month, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) returned 13.60%, but its shares are down 44.94% over the past year. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has a market capitalization of $34.52 billion, and its stock has traded within a 52-week range of $197.81 to $495.55.

American Century Investments Focused Dynamic Growth Fund stated the following regarding Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in its Q2 2026 investor letter:

"Stock choices and a sector overweight relative to the benchmark detracted as many biotechnology stocks, including Alnylam Pharmaceuticals and Insmed, underperformed the market. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The biotechnology company's stock underperformed amid concerns of its upcoming late-stage clinical trial readouts despite what we believed was its otherwise strong recent financial performance."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge fund portfolios held Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) at the end of the second quarter, which was 54 in the previous quarter. While we acknowledge the potential of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we discussed Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and highlighted why the company's best quarter ever did not translate into a richer valuation. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.